Fingerprint
Dive into the research topics of 'Delayed-release oral mesalamine 4.8 g/day (800 mg tablets) compared with 2.4 g/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: The ASCENDI trial'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically